X

Trial Profile

A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Safety and Efficacy of OMS721 in Patients with Immunoglobulin A (IgA) Nephropathy (ARTEMIS -IGAN)

Status: Discontinued

Phase of Trial: Phase III

Latest Information Update: 30 May 2024

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Narsoplimab (Primary)
Indications IgA nephropathy
Focus Registrational; Therapeutic Use
Acronyms ARTEMIS-IGAN
Sponsors Omeros Corporation

Most Recent Events

07 May 2024 This trial has been completed in Germany, according to European Clinical Trials Database record.
21 Mar 2024 This trial has been completed in Sweden (global end date: 2023-09-11), according to European Clinical Trials Database.
04 Feb 2024 This trial has been discontinued in Italy, according to European Clinical Trials Database.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com